New hope for advanced breast cancer: experimental drug FWD1802 enters human trials
NCT ID NCT06064812
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called FWD1802 in people with a common type of advanced breast cancer (ER+/HER2-). The goal is to find a safe dose and see if it can shrink tumors. About 99 women with cancer that has spread or cannot be removed by surgery will take part. The study has two phases: first to check safety, then to measure how well the drug works.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER STAGE IV are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
First Affiliated Hospital of China Medical University
RECRUITINGShenyang, Liaoning, China
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, 200032, China
-
Guangxi Medical University Cancer Hospital
RECRUITINGNanning, Guangxi, China
-
Henan Cancer Hospital
RECRUITINGZhengzhou, Henan, China
-
Hubei Cancer Hospital
NOT_YET_RECRUITINGWuhan, Hubei, China
-
Huizhou First Hospital
RECRUITINGHuizhou, Guangdong, China
-
Jiangsu Province Hospital
RECRUITINGNanjing, Jiangsu, China
-
Jilin Cancer Hospital
RECRUITINGChangchun, Jilin, China
-
Liaoning Cancer Hospital & Institute
RECRUITINGShenyang, Liaoning, China
-
Shandong Cancer Hospital
RECRUITINGJinan, Shandong, China
-
Sichuan Cancer Hospital
RECRUITINGChengdu, Sichuan, China
-
Sir Run Run Shaw Hospital,affiliated with Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, China
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, China
-
The Central Hospital of Yongzhou
RECRUITINGYongzhou, Hunan, China
-
The First Affiliated Hospital of Henan University of Science & Technology
RECRUITINGLuoyang, Henan, China
-
The First Affiliated Hospital of Zhengzhou University
NOT_YET_RECRUITINGZhengzhou, Henan, China
-
The First Hospital of Jilin University
RECRUITINGChangchun, Jilin, China
-
The Second Hospital of Anhui Medical University
RECRUITINGHefei, Anhui, China
-
The second people's hospital of Yibin
RECRUITINGYibin, Sichuan, China
-
Tianjin Medical University Cancer institute & Hospital
RECRUITINGTianjin, Tianjin Municipality, China
-
Xinxiang Central Hospital
RECRUITINGXinxiang, Henan, China
-
Zhejiang Cancer Hospital
RECRUITINGHangzhou, Zhejiang, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Drug attack shrink Hard-to-Treat breast cancer?
- Can mapping tumor DNA unlock personalized breast cancer care?
- Could a personal coach at home boost energy for cancer patients?
- Can an immune booster help chemotherapy fight metastatic breast cancer?
- Can a Four-Drug cocktail tame a tough breast cancer?
- Can a new drug outsmart resistant breast cancer?